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Background—The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory
drugs (NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established
cardiovascular disease is unknown. We analyzed the risk of rehospitalization for acute myocardial infarction (MI) and
death related to the use of NSAIDs including selective COX-2 inhibitors in patients with prior MI.
Methods and Results—All patients with first-time MI between 1995 and 2002 as well as all prescription claims for
NSAIDs after discharge were identified from nationwide Danish administrative registers. The risk of death and
rehospitalization for MI associated with the use of selective COX-2 inhibitors and nonselective NSAIDs was studied
with the use of multivariable proportional hazards models and case-crossover analysis. A total of 58 432 patients were
discharged alive and included in the study; 9773 experienced rehospitalization for MI, and 16 573 died. A total of 5.2%
of patients received rofecoxib, 4.3% celecoxib, 17.5% ibuprofen, 10.6% diclofenac, and 12.7% other NSAIDs. For any
use of rofecoxib, celecoxib, ibuprofen, diclofenac, and other NSAIDs, the hazard ratios and 95% confidence intervals
for death were 2.80 (2.41 to 3.25; for rofecoxib), 2.57 (2.15 to 3.08; for celecoxib), 1.50 (1.36 to 1.67; for ibuprofen),
2.40 (2.09 to 2.80; for diclofenac), and 1.29 (1.16 to 1.43; for other NSAIDS); there were dose-related increases in risk
of death for all of the drugs. There were trends for increased risk of rehospitalization for MI associated with the use of
both the selective COX-2 inhibitors and the nonselective NSAIDs.
Conclusions—Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages increase mortality in
patients with previous MI and should therefore be used with particular caution in these patients. (Circulation. 2006;113:
2906-2913.)
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The selective cyclooxygenase-2 (COX-2) inhibitors havebeen used widely for the treatment of pain and rheumatic
disease since they were introduced in the late 1990s. How-
ever, the use of the COX-2 inhibitors and the associated
excess cardiovascular risk has caused increasing concern
since the publication of the Vioxx Gastrointestinal Outcomes
Research (VIGOR) study1 in 2000. Although some studies
have reported mixed results with regard to the cardiovascular
risk,2–4 several recently published randomized trials and
population-based studies have established an increased risk of
acute myocardial infarction (MI) and thromboembolic events
related to the use of most COX-2 inhibitors.5–14 This caused the
pharmaceutical company Merck to withdraw their COX-2 in-
hibitor rofecoxib (Vioxx) from the market, and health authorities
in several countries have issued a warning about the cardiovas-
cular risk associated with the use of COX-2 inhibitors.
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The more traditional nonselective nonsteroidal antiinflam-
matory drugs (NSAIDs) have long been used uncritically in
the treatment of pain and rheumatic diseases, but knowledge
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about the cardiovascular safety of the nonselective NSAIDs is
sparse. Nevertheless, results from recently published
population-based studies have also raised concern about the
cardiovascular risk of NSAIDs in general.9,15,16
Patients with acute MI have an increased risk of recurrent
MI and death. Little is known about the extent to which the
cardiovascular risk of selective COX-2 inhibitors relates to
this population and whether other nonselective NSAIDs are
also associated with increased risk. Therefore, we used
nationwide administrative registers of hospitalization and
drug dispensing from pharmacies in Denmark to study the
risk of recurrent MI and death related to the use of selective
COX-2 inhibitors and nonselective NSAIDs in patients dis-
charged after first-time acute MI between 1995 and 2002.
Methods
The Danish National Patient Registry has since 1978 registered all
hospital admissions in Denmark. Each admission is registered by 1
primary diagnosis and 1 or more secondary diagnoses by the
International Classification of Diseases (ICD), until 1994 the ICD-8
and from 1994 the ICD-10.
The Danish Registry of Medicinal Product Statistics (national
prescription registry) has since 1995 kept records of every prescrip-
tion dispensed from pharmacies in Denmark. Each medication is
classified by the Anatomical Therapeutical Chemical system, and the
registry also includes information about the date of dispensing,
formulation, strength, and quantity dispensed. Information on pa-
tients’ vital status (dead or alive) was obtained from the civil
registration system through Statistics Denmark. In Denmark, every
resident is provided with a permanent and unique civil registration
number that enables linkage between these administrative registries.
Population
From the National Patient Registry we identified all patients, aged
30 years, hospitalized with acute MI (ICD-10 code I21 to I22) for
the first time between 1995 and 2002. The diagnosis of acute MI has
been validated in the National Patient Registry, with a specificity of
90%.17 A more detailed description of selection of patients has
been published previously.18 All patients who were alive at discharge
were included in the present study and analyzed for the risk of death
and rehospitalization for MI.
Drug Use
From the national prescription registry, all claimed prescriptions of
NSAIDs (Anatomical Therapeutical Chemical code M01A) by the
study cohort were identified. The 2 most frequently used COX-2
inhibitors, rofecoxib (M01AH02) and celecoxib (M01AH01), were
analyzed separately because they represented 90% of all COX-2
inhibitors used. Similarly, the nonselective NSAIDs ibuprofen
(M01AE01) and diclofenac (M01AB05) represented the majority of
nonselective NSAIDs used and were therefore analyzed separately.
All other NSAIDs were categorized as 1 group in the analyses.
Dosages
The national prescription registry does not include information on
prescribed daily dosage of the medication. Therefore, by calculating
average dosages from up to 3 consecutive prescriptions, the daily
dosage was estimated at each new prescription dispensing. This
method allowed for dosages to change at dispensing of a new
prescription. The method has been described in detail previously.19
To analyze whether there was a dose-related response in risk of death
or rehospitalization for MI, the 2 COX-2 inhibitors (rofecoxib and
celecoxib) and the 2 nonselective NSAIDs (ibuprofen and diclofe-
nac) were divided into low or high dosages. The upper limit of low
dosage was defined as the lower recommended daily dosage for the
individual NSAIDs, ie, 25 for rofecoxib, 200 for celecoxib, 1200 for
ibuprofen, and 100 mg for diclofenac. NSAIDs other than the
aforementioned ones were not divided into specific dosages.
Comorbidity and Socioeconomic Status
Comorbidity was defined from diagnoses at discharge from index MI
as specified in the Ontario acute MI mortality prediction rule.20 The
comorbidity index was further enhanced by adding diagnoses from
the year before the event, as done by Rasmussen et al.21 Diagnoses
used in the comorbidity index are shown in Table 1. Socioeconomic
status was defined by the individual average yearly gross income
during a 5-year period before the index MI (excluding the year of
index MI). Patients were divided into tertiles according to income.
Statistical Analysis
To ensure the strength of our findings, we used 2 different statistical
methods to estimate the risk of taking selective COX-2 inhibitors or
nonselective NSAIDs after an MI. At first, Cox proportional hazards
models were used when the exposure covariates (drug) were in-
cluded as time-dependent variables, meaning that patients were only
considered at risk when they were taking the drug. The Cox models
were adjusted for age, gender, year of first MI, length of treatment,
concomitant medical treatment (Table 1), socioeconomic status, and
comorbidity. Model assumptions—the linearity of continuous vari-
ables, the proportional hazards assumption, and lack of interaction—
were tested and found valid unless otherwise indicated. The other
method was the case-crossover design with the use of conditional
logistic regression.22 The case-crossover design is based on the
case-base paradigm, but instead of using matched controls, the case
serves as its own control. Only patients experiencing an event of
interest are included in the case-crossover analysis. Among these
patients, the number having medication available in the case period
(which is the period immediately before the event of interest) is
compared with the number having medication available in the
control period (which is a period further back in time than the case
period but of the same length as the case period). The case-crossover
design eliminates the effect of many potential confounders by
keeping characteristics such as age, sex, socioeconomic status, and
comorbidity fixed. We defined the case period as 0 to 30 days before
the event (MI or death), and, to enhance the strength of the analyses,
we selected 2 control periods as 60 to 90 and 90 to 120 days before
the event. The numbers needed to harm (NNH) were calculated for
each drug from unadjusted mortality ratios. All statistical calcula-
tions were performed with the SAS statistical software package
version 8.2 for UNIX servers (SAS Institute Inc, Cary, NC).
Ethics
The Danish Data Protection Agency approved this study, and data at
the individual level were made available to us such that specific
individuals could not be identified. Retrospective register studies do
not require ethical approval in Denmark.
The authors had full access to the data and take responsibility for
its integrity. All authors have read and agree to the manuscript as
written.
Results
The total of 71 515 patients were admitted with first-time MI during
1995–2002; 58 432 (81.7%) were alive at discharge and included in
the study. After discharge, 21 093 patients (36.1%) claimed at least
1 prescription of 1 of the NSAIDs. A detailed description of
baseline characteristics of the study population and distribution
between treatment groups is shown in Table 1. Patients taking
nonselective NSAIDs were younger and more were male than
patients taking selective COX-2 inhibitors, but otherwise there were
no major differences between the treatment groups.
The duration of treatment was similar with rofecoxib,
celecoxib, and ibuprofen, at 37 to 40 days, but the duration of
treatment was only 20 days for diclofenac and 83 days for
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other NSAIDs (Table 2). There were 9773 rehospitalizations
(18.6%) for MI and 16 561 deaths (28.3%) during the
observation period. Higher death rates were associated with
exposure to all of the NSAIDs compared with nonexposure,
but the death rates were highest among those exposed to
rofecoxib and celecoxib (Table 2). The NNH values were
calculated from unadjusted mortality ratios and are shown as
number of patients needed to treat with each drug for 1 year
to cause 1 additional death (Table 2).
Cox Proportional Hazards Analysis
Results from the Cox proportional hazards analysis for hazard
ratios for death and rehospitalization for MI are shown in
Table 3 and illustrated in Figures 1 and 2. There was
significantly increased risk of death associated with any use
of both the nonselective NSAIDs and the selective COX-2
inhibitors. After the most commonly used nonselective
NSAIDs, ibuprofen and diclofenac, and selective COX-2
inhibitors, rofecoxib and celecoxib, were divided into low












Total patients 58 432 3022 2489 10 230 6172 7449
Age, meanSD, y 68.012.9 69.212.1 69.211.9 64.713.0 64.512.5 66.712.6
Women 21 737 (37.2) 1511 (50.0) 1240 (49.8) 3506 (34.3) 2083 (33.7) 2932 (39.4)
Men 36 695 (62.8) 1511 (50.0) 1249 (50.2) 6724 (65.7) 4089 (66.3) 4517 (60.6)
Comorbidity
Congestive heart failure 7525 (12.9) 331 (11.0) 284 (11.4) 851 (8.3) 506 (8.2) 720 (9.7)
Cardiac arrhythmias 5316 (9.1) 258 (8.5) 197 (7.9) 625 (6.1) 400 (6.5) 520 (7.0)
Peripheral vascular disease 1026 (1.8) 41 (1.4) 34 (1.4) 125 (1.2) 78 (1.3) 97 (1.3)
Cerebral vascular disease 2532 (4.3) 112 (3.7) 84 (3.4) 255 (2.5) 160 (2.6) 204 (2.7)
Diabetes with complications 2190 (3.8) 105 (3.5) 85 (3.4) 326 (3.2) 167 (2.7) 193 (2.6)
Acute renal failure 395 (0.7) 14 (0.5) 7 (0.3) 30 (0.3) 13 (0.2) 19 (0.3)
Chronic renal failure 546 (0.9) 20 (0.7) 14 (0.6) 54 (0.5) 24 (0.4) 25 (0.3)
Malignancy 1425 (2.4) 66 (2.2) 51 (2.1) 160 (1.6) 96 (1.6) 135 (1.8)
Shock 435 (0.7) 25 (0.8) 14 (0.6) 43 (0.4) 23 (0.4) 35 (0.5)
COPD 3272 (5.6) 171 (5.7) 147 (5.9) 457 (4.5) 271 (4.4) 331 (4.5)
Gastric ulcer 1106 (1.9) 79 (2.6) 50 (2.0) 97 (1.0) 64 (1.0) 117 (1.6)
Concomitant medical treatment
-Blockers 32 737 (56.7) 1739 (57.6) 1497 (60.2) 5842 (57.2) 3678 (59.7) 4140 (55.6)
Angiotensin-converting enzyme inhibitors 16 501 (28.6) 853 (28.3) 668 (26.9) 2585 (25.3) 1613 (26.2) 1987 (26.7)
Statins 16 795 (31.1) 936 (31.7) 751 (31.1) 3131 (31.0) 1909 (31.3) 1952 (26.5)
Loop diuretics 21 820 (37.3) 1180 (39.1) 989 (39.7) 3288 (32.2) 1877 (30.4) 2677 (36.0)
Antidiabetic drugs 5965 (10.2) 304 (10.1) 240 (9.6) 1002 (9.8) 583 (9.5) 672 (9.0)
Values are number (%). COPD indicates chronic obstructive pulmonary disease.
TABLE 2. Average Dosages, Average Duration of Treatment, Number of Deaths, and Time Exposed to Drug and Death Rate Related



















Rofecoxib 3022 (5.2) 25 (12.5–25) 39 (14–224) 152‡ 896§ 169 (144–198) 13 (10–20)
Celecoxib 2489 (4.3) 200 (200–200) 40 (20–181) 112‡ 675§ 165 (137–198) 14 (10–24)
Ibuprofen 10 230 (17.5) 1600 (1200–1800) 37 (10–463) 313‡ 2669§ 117 (105–131) 45 (29–102)
Diclofenac 6172 (10.6) 100 (100–150) 20 (10–272) 160‡ 1167§ 137 (117–160) 24 (16–45)
Other NSAIDs 7449 (12.7)    83 (20–461) 348‡ 3402§ 102 (92–113) 143 (58–315)
No NSAIDs 37 339 (63.9)       15 476 163 059 95 (94–97)   
Total study cohort 58 432       16 561 171 868 96 (95–97)   
*Median (interquartile range).
†Unadjusted for confounders.
‡Deaths while receiving treatment.
§Total person-years in treatment.
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and high dosages, the Cox proportional hazards analysis
demonstrated a clear dose-related response in the increase in
the risk of death for all drugs. There was a trend for increased
risk of readmission for MI related to the use of both the
selective COX-2 inhibitors and nonselective NSAIDs; how-
ever, the dose-related increase in risk was not as evident as
that observed for death.
Case-Crossover Analyses
Odds ratios for death and readmission for MI from the
conditional logistic regression analyses with the use of the
case-crossover design are shown in Table 4. These analyses
confirmed the results of the Cox proportional hazards analy-
ses, with increased risk of death associated with any use of
both the nonselective NSAIDs and the selective COX-2
inhibitors and higher risk with higher dosages. The trend for
increased risk of readmission for MI was even more evident
in the case-crossover analyses.
Supplementary Analyses
We tested for interactions for each of the COX-2 inhibitors
and NSAIDs with available covariates, and the analyses were
repeated in subgroups of sex and median age with similar
results. There were no important interactions with available
covariates.
Discussion
This study demonstrated dose-related excess mortality asso-
ciated with the use of NSAIDs in patients with prior MI.
There was a trend for increased risk of rehospitalization for
MI, although the dose-related response in risk was not as
clear as for death.
The VIGOR study was the first to report increased cardio-
vascular risk associated with the selective COX-2 inhibitors.1
Since then, several studies,5,6,8,12,23 although not all,2,24–26
have confirmed the findings. Several recently published
observational studies have also indicated an increased cardio-
vascular risk associated with the nonselective NSAIDs.7–9,13
The present study is the first to address the risk of all
NSAIDs in a selected population of post-MI patients. These
patients are elderly, are frequently treated with NSAIDs, and
have a high risk of additional cardiovascular events. Many of
the randomized trials have excluded these patients. The
results of the present study indicate acute or subacute effects
of both the selective COX-2 inhibitors and nonselective
NSAIDs on the cardiovascular system because events were
closely tied to the timing of taking the drugs, and most
patients were receiving treatment for a short time. In the
Adenomatous Polyp Prevention on Vioxx (APPROVe) study,
increased risk of thrombotic events associated with use of
TABLE 3. Hazard Ratios for Death and Rehospitalization for MI; Cox Proportional Hazards Analysis*
Drug
Death Re-MI
No. of Events† HR (95% CI) P No. of Events† HR (95% CI) P
Rofecoxib (n3022)
No use‡ 1.00 1.00
Any use 152 2.80 (2.41–3.25) 0.0001 59 1.63 (1.27–2.10) 0.0001
Daily dose 25 mg 106 2.49 (2.11–2.94) 0.0001 53 1.68 (1.30–2.17) 0.0001
Daily dose 25 mg 46 5.26 (3.90–7.09) 0.0001 6 1.27 (0.57–2.86) 0.56
Celecoxib (n2489)
No use‡ 1.00 1.00
Any use 112 2.57 (2.15–3.08) 0.0001 42 1.50 (1.10–2.05) 0.01
Daily dose 200 mg 54 1.92 (1.52–2.43) 0.0001 36 1.47 (1.03–2.09) 0.03
Daily dose 200 mg 58 4.69 (3.58–6.14) 0.0001 6 1.64 (0.91–2.90) 0.10
Ibuprofen
No use‡ 1.00 1.00
Any use 266 1.50 (1.36–1.67) 0.0001 136 1.25 (1.07–1.46) 0.005
Daily dose 1200 mg 47 0.75 (0.61–0.92) 0.006 77 1.28 (1.03–1.60) 0.03
Daily dose 1200 mg 219 2.20 (1.95–2.48) 0.0001 59 1.22 (0.99–1.51) 0.055
Diclofenac
No use‡ 1.00 1.00
Any use 160 2.40 (2.09–2.80) 0.0001 61 1.54 (1.23–1.93) 0.0002
Daily dose 100 mg 28 0.89 (0.66–1.20) 0.45 40 1.27 (0.92–1.76) 0.15
Daily dose 100 mg 132 4.44 (3.79–5.19) 0.0001 21 1.89 (1.40–2.55) 0.0001
Other NSAIDs
No use‡ 1.00 1.00
Any use 348 1.29 (1.16–1.43) 0.0001 14 1.27 (1.09–1.47) 0.002
Re-MI indicates rehospitalization for MI; HR, hazard ratio.
*Adjusted for age, gender, year of MI, concomitant medical treatment, socioeconomic status, and comorbidity.
†No. of events while having drug available for treatment.
‡Reference group.
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rofecoxib only became apparent after 18 months of treatment,
but there was an earlier separation between groups in the
incidence of heart failure after 5 months of treatment.5 The
Adenoma Prevention with Celecoxib (APC) study was
stopped because of excess cardiovascular events and deaths
after 3 years, but the survival curves began to diverge after 12
months.6 A study by Nussmeier et al12 on patients after
coronary artery bypass graft surgery found increased cardio-
vascular risk after only 10 days of treatment with selective
COX-2 inhibitors. A meta-analysis by Juni et al23 found no
association between duration of treatment with rofecoxib and
cardiovascular risk, and other observational studies have
shown that recent use of NSAIDs increases risk, whereas risk
of remote use is less apparent.7,9 Current data therefore
suggest harmful effects after short-term as well as after
long-term treatment. This may be influenced further by the
baseline cardiovascular risk of the individual patient.
Prior observational studies have failed to show increased
cardiovascular risk of the selective COX-2 inhibitor cele-
coxib.7,8,10 In the present study the risks associated with
celecoxib and rofecoxib could be compared directly and were
similar. This increases the likelihood that the harmful effects
can be attributed to the drug class rather than the peculiarities
of one of the drugs. Because the population in the present
study comprised post-MI patients, this might indicate more
abrupt effects on a vulnerable cardiovascular system, and the
Figure 1. Hazard ratios for the risk of
death associated with the use of selec-
tive COX-2 inhibitors and nonselective
NSAIDs after acute MI. Adjusted for age,
sex, year of MI, concomitant medical
treatment, socioeconomic status, and
comorbidity. Reference group: no use of
COX-2 inhibitors or NSAIDs. Error bars
indicate 95% CIs.
Figure 2. Hazard ratios for the risk of
readmission for MI associated with the
use of selective COX-2 inhibitors and
nonselective NSAIDs after acute myocar-
dial infarction. Adjusted for age, sex,
year of MI, concomitant medical treat-
ment, socioeconomic status, and comor-
bidity. Reference group: no use of
COX-2 inhibitors or NSAIDs. Error bars
indicate 95% CIs.
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harmful effects of celecoxib may therefore become more
apparent than in previous studies.
The dose relationship found in this study is overall in
agreement with previous studies.5,6,8 The upper limit of low
dosage was in this study defined as the lower limit of
recommended daily dosage for the individual NSAIDs stud-
ied, but there may be differences in pharmacological proper-
ties of the individual NSAIDs not accounted for in the current
definition. Nevertheless, the increased risk associated with
any use of the selective COX-2 inhibitors and high dosages of
the 2 nonselective NSAIDs, demonstrated in the present
study, needs to be acknowledged.
Most patients receive treatment with low-dose acetylsali-
cylic acid (aspirin) after MI to prevent recurrent cardiovas-
cular events.27 The effect of aspirin on the associated excess
cardiovascular risk of COX-2 inhibitors has been the subject
of debate, and some studies have excluded patients receiving
aspirin. The Therapeutic Arthritis Research and Gastrointes-
tinal Event Trial (TARGET) involved treatment with lumira-
coxib, stratified to the concomitant use of aspirin. There was
an insignificant trend toward lower incidence of cardiovas-
cular events in the lumiracoxib group receiving concomitant
aspirin compared with those who did not receive aspirin.28
Therefore, the relatively low risk of recurrent MI observed in
the present study compared with the risk of death may be due
to the protective role of aspirin. Another contributing factor
may be that many patients died out of hospital, perhaps
because of recurrent infarctions.
The prostanoids are generated from arachidonic acid by
COX-1– and COX-2–mediated metabolism and have a wide
range of biological actions. A detailed discussion of the
potential mechanisms has been published previously.29,30 In
brief, COX-1 is involved in the generation of thromboxane
A2, which is a vasoconstrictor and platelet agonist and
promotes smooth muscle proliferation. COX-2 mediates syn-
thesis of prostaglandin I2, which is a potent vasodilator,
inhibits platelet function, and promotes renal sodium excre-
tion. Platelets express only COX-1, but endothelial cells
express both COX-1 and COX-2.
An unbalanced inhibition of only COX-2 therefore early
caused some concern about cardiovascular side effects, but
the theory of balanced versus unbalanced COX inhibition is
now debatable because the nonselective NSAIDs are also
associated with increased cardiovascular risk. However, other
mechanisms may explain the harmful effects of NSAIDs on
the cardiovascular system. Ibuprofen has been found to
compete with low-dose aspirin in binding to the COX-1
pathway in the platelets, but, in contrast to low-dose aspirin,
the block is not irreversible and therefore leaves the patient
only partially protected against thrombosis.31 Furthermore,
TABLE 4. Odds Ratios for Death and Rehospitalization for MI: Conditional
Logistic Regression Analysis by the Case-Crossover Design*
Death Re-MI
Drug and Daily Dosage OR 95% CI P OR 95% CI P
Rofecoxib
No use 1.00 1.00
Any use 2.36 1.75–3.19 0.0001 2.46 1.42–4.24 0.001
Daily dose 25 mg 1.96 1.43–2.69 0.0001 2.37 1.35–4.16 0.003
Daily dose 25 mg 8.65 3.71–20.1 0.0001 3.73 0.67–20.6 0.13
Celecoxib
No use 1.00 1.00
Any use 2.37 1.68–3.35 0.0001 1.36 0.73–2.53 0.34
Daily dose 200 mg 1.97 1.33–2.93 0.001 1.01 0.50–2.02 0.98
Daily dose 200 mg 3.88 2.04–7.36 0.0001 5.27 1.07–25.9 0.04
Ibuprofen
No use 1.00 1.00
Any use 1.05 0.88–1.24 0.61 1.32 1.02–1.72 0.04
Daily dose 1200 mg 0.57 0.45–0.74 0.0001 1.41 0.95–2.08 0.08
Daily dose 1200 mg 1.65 1.33–2.04 0.0001 1.26 0.89–1.78 0.19
Diclofenac
No use 1.00 1.00
Any use 1.59 1.28–1.98 0.0001 1.67 1.15–2.42 0.007
Daily dose 100 mg 0.86 0.63–1.17 0.34 1.66 1.04–2.63 0.03
Daily dose 100 mg 2.82 2.08–3.83 0.0001 1.69 0.96–2.98 0.07
Other NSAIDs
No use 1.00 1.00
Any use 1.14 0.93–1.39 0.20 1.07 0.77–1.48 0.70
Re–MI indicates rehospitalization for MI; OR, odds ratio.
*Case period 0–30 days before event and control periods 60–90 and 90–120 days before event.
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clinical and observational studies have demonstrated in-
creased risk of heart failure, fluid retention, destabilization of
blood pressure control, and development of hypertension
associated with the use of selective COX-2 inhibitors and
nonselective NSAIDs.32–35 In addition, animal models indi-
cate that imbalance in thromboxane A2/prostaglandin I2 ho-
meostasis could promote cardiac fibrosis and cardiac hyper-
trophy as well as modulate response to endothelial injury.30,36
Previous studies have focused mainly on combined end
points, whereas we are able to demonstrate an association
with all-cause mortality. We find low NNH values (Table 2)
for COX-2 inhibitors and high-dosage nonselective NSAIDs,
whereas in the APC trial NNH for a combined end point is
70. This illustrates that the harmful effects of these drugs
appear much more severe in patients with a previous MI.
Strengths and Limitations of the Study
The Danish National Patient Registry as well as the national
prescription registry have been shown to be accurate.17,37 In
Denmark, ibuprofen is the only NSAID that is available
over-the-counter without prescription and only in a low
dosage and limited quantity at each dispensing. Therefore, it
is unlikely that over-the-counter use of NSAIDs has a major
impact on this study. We assumed that most of our patients
used aspirin on a daily basis, as shown in epidemiological
surveys of post-MI patients.27 If aspirin use was lower in the
group taking NSAIDs, a higher event rate would be expected
in that group, but because aspirin is primarily dispensed over
the counter, the effects of aspirin cannot be assessed properly.
The Cox models used provide control of available confound-
ers, but the control for confounding by indication—that the
patients put on treatment are sicker than those not treated—
may not be adequate. For this reason, we performed supple-
mentary analyses using the case-crossover design. By using
the case as its own control, the effects of chronic confounders
are almost eliminated. Confounding is still possible, however.
If the risk of death was increased by the pain-eliciting
conditions only, the observed association between COX-2
and NSAID intake and increased risk of death would be due
to confounding. Whereas such confounding cannot be ex-
cluded in an observational study, the dose-response effect, the
different effect of different drugs used for similar indications,
and the clear relation between degree of COX-2 inhibition
and risk all indicate the importance of the drugs rather than
the indications.
Conclusions and Clinical Implications of the Study
The present study demonstrates that treatment with 2 COX-2
inhibitors and high dosages of 2 nonselective NSAIDs are
associated with a highly increased risk of death in patients
with prior MI. The results add important information to the
treatment of high-risk patients, notably those with prior MI,
and must be viewed together with the rest of the evidence.
Given the additional evidence from randomized trials and
other observational studies of selective COX-2 inhibitors and
nonselective NSAIDs, these drugs should be used with
particular caution in patients with a prior MI. Post-MI
patients with pain conditions relieved by these drugs should
discuss carefully with their doctor the balance between
benefits and risk of treatment.
Because studies in this field have revealed major safety
concerns where none were thought present, the cardiovascu-
lar safety of not only the selective COX-2 inhibitors but of all
NSAIDs needs to be addressed further.
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CLINICAL PERSPECTIVE
Some nonsteroidal antiinflammatory drugs (NSAIDs) are associated with increased cardiovascular risk in patients without
known cardiovascular disease. Because these drugs are used frequently in patients with cardiovascular disease, it is of
particular importance to know the risk in these patients. We used nationwide Danish registers on hospital admissions,
pharmacy prescriptions, and mortality to study the risk of selective cyclooxygenase-2 (COX-2) inhibitors and nonselective
NSAIDs in patients with a myocardial infarction. The study shows an increased risk of death associated with any use of
the COX-2 inhibitors rofecoxib and celecoxib and a dose-related increase in risk. Furthermore, there was an increased risk
associated with high dosages of the nonselective NSAIDs ibuprofen and diclofenac, whereas low dosages of these drugs
did not appear harmful. There was also increased risk of reinfarction, but the dose relation was less clear than for death.
Therefore, in patients with prior myocardial infarction, high dosages of NSAIDs or any dosages of COX-2 inhibitors
should, if at all possible, be avoided and only used with caution, balancing benefit with a substantial increase in risk of
death and reinfarction.
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